Adequate platelet inhibition is mandatory in patients undergoing percutaneous coronary intervention in order to prevent recurrent thrombotic events. Dual antiplatelet therapy with aspirin and thienopyridine (e.g., clopidogrel) is the treatment of choice in this setting, providing clear clinical benefit in most of the patients. However, a wide interindividual variability exists in the response to antiplatelet drugs and several factors may contribute to determine fluctuation in platelet reactivity, even within the individual patient. Several methodologies and devices have been developed to monitor individual response to antiplatelet treatment, assessing different pathways of platelet activation and aggregation. Studies performed with the use of these methodologies have clearly demonstrated that patients with high post-treatment residual platelet reactivity present a higher risk of ischemic events both at short (during or soon after percutaneous coronary intervention) and long term. In these patients, more aggressive antithrombotic strategies, based on the results of platelet function tests, may be beneficial in order to reduce ischemic complications after percutaneous coronary intervention. © 2010 Future Medicine Ltd.

Residual platelet reactivity: Predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization / Mangiacapra, Fabio; Barbato, Emanuele. - In: BIOMARKERS IN MEDICINE. - ISSN 1752-0363. - 4:3(2010), pp. 421-434. [10.2217/bmm.10.56]

Residual platelet reactivity: Predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization

BARBATO, EMANUELE
2010

Abstract

Adequate platelet inhibition is mandatory in patients undergoing percutaneous coronary intervention in order to prevent recurrent thrombotic events. Dual antiplatelet therapy with aspirin and thienopyridine (e.g., clopidogrel) is the treatment of choice in this setting, providing clear clinical benefit in most of the patients. However, a wide interindividual variability exists in the response to antiplatelet drugs and several factors may contribute to determine fluctuation in platelet reactivity, even within the individual patient. Several methodologies and devices have been developed to monitor individual response to antiplatelet treatment, assessing different pathways of platelet activation and aggregation. Studies performed with the use of these methodologies have clearly demonstrated that patients with high post-treatment residual platelet reactivity present a higher risk of ischemic events both at short (during or soon after percutaneous coronary intervention) and long term. In these patients, more aggressive antithrombotic strategies, based on the results of platelet function tests, may be beneficial in order to reduce ischemic complications after percutaneous coronary intervention. © 2010 Future Medicine Ltd.
2010
acetylsalicylic acid; anticoagulant agent; atorvastatin; clopidogrel; cyclooxygenase 1; fibrinogen receptor; fibrinogen receptor antagonist; heparin; omeprazole; prasugrel; proton pump inhibitor; purinergic P2Y12 receptor; thienopyridine derivative; ticagrelor; acute heart infarction; analyzer; anticoagulation; bleeding; body mass; clinical practice; coronary artery atherosclerosis; coronary artery bypass graft; coronary artery disease; coronary stent; device; diabetes mellitus; disease severity; drug dose comparison; drug eluting stent; drug potency; drug targeting; flow cytometry; follow up; gene mutation; genetic polymorphism; gold standard; heart death; heart muscle revascularization; human; light transmittance aggregometry; loading drug dose; patient monitoring; percutaneous coronary intervention; point of care testing; practice guideline; prediction; protein phosphorylation; review; ST segment elevation myocardial infarction; stroke; thrombocyte activation; thrombocyte aggregation inhibition; thrombocyte function; thromboelastography; thrombosis; treatment outcome; treatment response; unstable angina pectoris; whole blood aggregometry; Angioplasty; Transluminal; Percutaneous Coronary; Aspirin; Blood Platelets; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Platelet Function Tests; Predictive Value of Tests; Recurrence; Ticlopidine; Aspirin; Clopidogrel; Percutaneous coronary intervention; Platelet; Platelet function test
01 Pubblicazione su rivista::01a Articolo in rivista
Residual platelet reactivity: Predicting short-and long-term clinical outcome in patients undergoing percutaneous coronary revascularization / Mangiacapra, Fabio; Barbato, Emanuele. - In: BIOMARKERS IN MEDICINE. - ISSN 1752-0363. - 4:3(2010), pp. 421-434. [10.2217/bmm.10.56]
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1660440
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 4
social impact